HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Tyra Biosciences, maintaining a price target of $32. This suggests confidence in the company's future performance.
October 29, 2024 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Tyra Biosciences, maintaining a price target of $32. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $32 price target by HC Wainwright & Co. indicates a positive outlook on Tyra Biosciences' stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100